Skip to main content
Clinical Trials/ISRCTN68849312
ISRCTN68849312
Completed
Not Applicable

Reversal of cerebrovascular endothelial dysfunction in diabetes: the effect of allopurinol upon cerebrovascular nitric oxide bioavailability

Greater Glasgow NHS Board/Glasgow University (UK)0 sites24 target enrollmentNovember 22, 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Greater Glasgow NHS Board/Glasgow University (UK)
Enrollment
24
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 22, 2005
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Greater Glasgow NHS Board/Glasgow University (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. Type II diabetes less than 5 years duration, treated with diet, metformin thiazolidinediones or a combination
  • 2\. Aged greater than 40 years
  • 3\. Normal full Bruce protocol exercise treadmill testing (ETT)
  • 4\. Favourable temporal bony window
  • 5\. HbA1c less than 9%
  • 6\. Cholesterol less than 7\.5 mmol/l

Exclusion Criteria

  • 1\. Greater than 70% Internal carotid artery stenosis
  • 2\. Known coronary artery disease
  • 3\. Other significant comorbidity
  • 4\. Contraindication to allopurinol
  • 5\. Concurrent therapy with azathioprine or 6\-mercaptopurine
  • 6\. Insulin or sulphonylurea treatment
  • 7\. Serum creatinine greater than 250 µmol/l

Outcomes

Primary Outcomes

Not specified

Similar Trials